- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Evolving Drug Safety Landscape: Implications for Pharma
01 December
A webinar outlining the implications of the changing regulatory landscape on the industry in the short to medium term - and what could be considered in developing strategies to increase the safety profile of products - is being hosted by ICON on Wednesday 9 December at 4 pm GMT. 'Politics, Regulators and Clinical Research' will feature panelists including ICON's Suzanne Gagnon, IMS Health's Nigel Burrows and Christopher-Paul Milne, associate director of the Tufts Center for the Study of Drug Development.
Senior pharma executives involved in the drug safety or/and outsourcing strategies for their organization are invited to attend the webinar, which will discuss "what the political reforms of today mean for clinical research tomorrow"; "how recently published draft regulations from the FDA (and the expected EMEA guidelines) address drug safety and what they mean for your organization"; and "what innovative strategies pharma/biotech companies can do to continue to deliver treatments in a cost effective way."
Click here to register for this event.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
